Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parametric Survival Analysis: Weibull and Exponential Methods01:14

Parametric Survival Analysis: Weibull and Exponential Methods

1.3K
Parametric survival analysis models survival data by assuming a specific probability distribution for the time until an event occurs. The Weibull and exponential distributions are two of the most commonly used methods in this context, due to their versatility and relatively straightforward application.
Weibull Distribution
The Weibull distribution is a flexible model used in parametric survival analysis. It can handle both increasing and decreasing hazard rates, depending on its shape parameter...
1.3K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

327
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
327
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

487
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
487
Model Approaches for Pharmacokinetic Data: Compartment Models01:14

Model Approaches for Pharmacokinetic Data: Compartment Models

863
Compartmental analysis is a widely adopted approach to characterizing drug pharmacokinetics. It uses compartment models that conceptualize the body as a collection of reversibly communicating compartments, each representing a group of tissues exhibiting similar drug distribution characteristics. The movement rate of the drug between these compartments is typically described by first-order kinetics.
Two primary types of compartment models are recognized: mammillary and catenary. The more...
863
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

778
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
778
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

720
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
720

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial.

JAMA surgery·2026
Same author

How should covariates be handled in randomized trials? Empirical evidence from 50 trials and recommendations for practice.

Journal of clinical epidemiology·2026
Same author

A quantitative framework to assess the potential of earlier cancer detection to improve cancer survival.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Histotripsy dose impacts tumor cellular damage and treatment outcomes in a preclinical model of hepatocellular carcinoma.

Scientific reports·2026
Same author

Gemcitabine plus nivolumab with carboplatin or oxaliplatin in cisplatin-ineligible patients with metastatic urothelial carcinoma: a randomized phase II trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

OPERA: a new algorithm for patient stratification based on partially ordered risk factors.

Biometrics·2026

Related Experiment Video

Updated: Apr 23, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

9.8K

Bayesian approach for flexible modeling of semicompeting risks data.

Baoguang Han1, Menggang Yu, James J Dignam

  • 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, U.S.A.

Statistics in Medicine
|October 3, 2014
PubMed
Summary
This summary is machine-generated.

This study introduces flexible Bayesian illness-death models for semicompeting risks data. The new approach improves prediction by modeling the association between non-terminal and terminal events, crucial for clinical trial analysis.

Keywords:
Markov chain Monte Carloillness-deathrandom effectssemicompeting risks

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K

Related Experiment Videos

Last Updated: Apr 23, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

9.8K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.3K
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

1.0K

Area of Science:

  • Biostatistics
  • Clinical Trials
  • Survival Analysis

Background:

  • Semicompeting risks data involve non-terminal and terminal events where the terminal event can censor the non-terminal event.
  • Accurately modeling the association between these events is vital for reliable predictions and understanding clinical trial outcomes.
  • Existing models like shared frailty models may not fully capture complex, heterogeneous associations.

Purpose of the Study:

  • To extend illness-death models for semicompeting risks data with flexible random effects.
  • To develop a unified Bayesian approach for modeling the association between non-terminal and terminal events.
  • To enhance the prediction of terminal events using information from non-terminal events.

Main Methods:

  • Proposed flexible random effects within illness-death models to capture heterogeneous associations.
  • Developed a unified Bayesian modeling framework for fitting and prediction.
  • Utilized existing software for model implementation and individual-specific event prediction.

Main Results:

  • The proposed flexible random effects models effectively capture heterogeneous association structures.
  • The Bayesian approach provides a unified framework for both model fitting and prediction.
  • Demonstrated the utility through simulation studies and analysis of breast cancer clinical trial data.

Conclusions:

  • The extended illness-death models offer a powerful tool for analyzing semicompeting risks data.
  • The Bayesian approach facilitates robust modeling and accurate prediction in complex survival data scenarios.
  • This methodology enhances the analysis of clinical trial data, particularly in oncology.